Ersodetug Phase 3 upLIFT: 12 of 16 Tumor Hyperinsulinism Patients Come Off IV Glucose
Rezolute says ersodetug met the bar in Phase 3 upLIFT: 13 of 16 patients with insulin-secreting tumors responded and 12 stopped IV glucose. BLAs planned for 2027.
Rezolute says ersodetug met the bar in Phase 3 upLIFT: 13 of 16 patients with insulin-secreting tumors responded and 12 stopped IV glucose. BLAs planned for 2027.